IN8bio, Inc. (INAB) Form 8-K Summary
Business Context and Reporting Period
IN8bio, Inc., a Delaware corporation, filed this Current Report on Form 8-K on August 6, 2026. The filing serves to announce the Company's financial results for the second quarter ended June 30, 2026. The Company is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not reproduced in the text of this 8-K.
Material Changes
No material changes versus the prior comparable period are described in the text of this filing. The document solely references the issuance of the Q2 2026 results press release.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, or risk factors. It explicitly states that the information in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor subject to the liabilities of that section, except as expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 6, 2026) for actual Q2 2026 financial figures.
- Verify the Company's emerging growth company status and any election regarding extended transition periods for accounting standards.
- Confirm the trading symbol (INAB) and exchange (Nasdaq) for current market data.
- Check for any subsequent filings that may incorporate the press release by reference.